Part of the Stock Digest group of websites: Visit Small Cap Stock Digest  

FDA Approves Country’s First Marijuana-Based Medicine

The Food and Drug Administration on Monday approved the country’s first drug derived from marijuana, a medication that treats two rare and devastating forms of epilepsy.

The drug, GW Pharmaceuticals’ Epidiolex, is made of cannabidiol, or CBD, a component of marijuana that does not give users a high. It is given as an oil, and in clinical trials, it was shown to reduce the number of seizures by about 40 percent in patients with Dravet or Lennox-Gastaut syndromes.

“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” FDA Commissioner Scott Gottlieb said in a statement. “And, the FDA is committed to this kind of careful scientific research and drug development.”

The FDA’s decision was expected. FDA officials had indicated they supported approving Epidiolex, and an advisory panel had unanimously recommended it get the green light. There was some concern about the drug’s effects on the liver, but experts have said this risk could be addressed by doctors as they monitor their patients during treatment.

Before GW can market Epidiolex, though, the Drug Enforcement Administration will have to reclassify CBD, which in this case, because it comes from marijuana, is considered a Schedule I drug, meaning it has no medical value and a high risk of abuse. The agency is expected to do so within 90 days.

“This approval is the culmination of GW’s many years of partnership with patients, their families, and physicians in the epilepsy community to develop a much needed, novel medicine,” GW CEO Justin Gover said in a statement. “These patients deserve and will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”

Click here to continue reading...

Subscribe to the SCSD email list and get the latest small cap stock activity directly to your inbox, for free.

MARKET SUMMARY

INDICES

Name Last Change
DOW 26662.30 0.96%
S&P 500 2929.42 0.73%
NASDAQ 8027.67 0.97%
TSX 16157.90 0.05%
TSX-V 716.96 0.00%
RTY 1713.24 0.60%

Technology

Name Last Change
APPL 220.60 1.01%
GOOG 1185.65 1.23%

@SmallCapDigest ON TWITTER

Part of the Stock Digest family of websites
Resource Stock Digest